CPhl worldwide Barcelona

Mix with the world of Pharma products, people & solutions

cphl-worldwide

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 36,000 visiting pharma professionals over three days. 2,500+ exhibitors from 150+ countries gather at the event to network and take advantage of more than 100 free industry seminars. Every sector of the pharmaceutical market is represented under one roof, this year in a new location in Barcelona. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.

The exhibition showcases cover the whole spectrum of pharmaceutical manufacturing and ingredients sourcing, offering products and services that cover the entire supply chain.

 Please visit our websites:

Barcelona Car Service Airport

Car Service Barcelona

Car Service Barcelona to Cruise Port

Chauffeur Barcelona airport

Car Service Madrid

Almirall purchase Poli Group

The transaction amounts to 365 million euros and 35 million if certain milestones met

Almirall Barcelona

The pharmaceutical Almirall has closed the deal to acquire the entire share capital of Poli Group Holding, the holding company Poly Group, as reported Monday the pharmaceutical to the National Securities Market Commission (CNMV).

At the end of last November, the company estimated the amount of the acquisition of 365 million euros, with the possibility of payment of 35 million euros in the case met certain milestones related to the development of the business.

This transaction achieves a structure Almirall R & D focused on dermatology, a proprietary technology and three drug products under development.

Poli Group, based in Lugano (Switzerland) and sells products in 70 countries, comprising three companies: Taurus Pharma GbmH, Polichem SA and Polichem. With it you get a structure Almirall R & D focused on dermatology, a proprietary technology and a pipeline of three clinical trials in the final stages of development.

The Swiss company generated between June 2014 and June 2015 net sales of about 85 million euros. The group has mainly specialized in dermatology products, and a powerful portfolio of gynecological and respiratory products.

Europe and Asia are the focus of the company, which has a diversified portfolio of proprietary drugs focused on dermatology. These are complemented by a “strong” portfolio of gynecological and respiratory products, as highlighted Almirall.

Courtesy Car Service Barcelona

Chauffeur Barcelona airport

Car Service Madrid

Catalan biotechnology

The Catalan Aelix achieved 11.5 million euros to create a vaccine against AIDS

Aelix Therapeutics

Aelix Therapeutics, the company created the first development consortium Hivacat HIV treatments, has secured funding of 11.5 million euros earmarked for their research to create a therapeutic vaccine immunogen -from HTI-, “the first one you can cure infection in a patient. ” In investing, led by Ysios Capital (venture capital specialized in life sciences based in Barcelona), participated the equity manager of La Caixa, Caixa Capital Risc, and the US fund Innovation Johnson & Johnson. Aelix Therapeutics is led by renowned scientists: its founders are Dr. Bonaventura Clotet, Josep Maria Gatell, Christian Brander and biotechnology entrepreneur Jordi Naval.

Besides the medical challenge of this operation (more than 36.9 million people have HIV in the world), its characters include a major landmark in science model of excellence in Catalonia: first, a project It involves cutting edge science (Can Ruti and hospital Clinic), local industry (Esteve), public capital (research budgets Generalitat, Government and European Union), philanthropic (Obra Social La Caixa) and private (Ysios, Caixa Capital Risc) has He has been able to attract international capital (Johnson & Johnson). “It is an example of the contribution of all actors in the Catalan scientific industry. This is already happening in Tel Aviv or Boston, and now in Barcelona, ​​”says Josep Lluís Sanfeliu, Ysios Capital partner.

Aelix working on a therapeutic vaccine. That is, “retrains the patient’s immune system. There are a dozen companies in the world with different approaches to it, all in early stages, “says Jordi Naval. “It’s a hot topic, working from different angles, and the data is good.” Aelix vision anticipates fewer side effects in patients and significantly reduced the cost of treatment. “This is our aim, still have to prove it, some time before the product reaches the market,” he added.

With the money earned now, Aelix be reached until 2019 to carry out studies to assess the safety and efficacy in infected patients, equivalent to Phase II clinical study. He has so far tested in animals, and later this year will begin testing in healthy volunteers and patients. “Then, depending on the results, we will think how to complete the trial with the phase III (involving thousands of patients in various countries is different scale), if investors, or a pharmaceutical incorporated”.

Hivacat is a consortium of public-private research created in 2006 by two research centers in more developed AIDS and international reference, the AIDS Research Institute IrsiCaixa-Hospital Universitari Germans Trias i Pujol-Can Ruti (who runs Bonaventura Clotet ) and the Department of Infectious Diseases and AIDS of Hospital Clínic de Barcelona (Josep Maria Gatell).

In 2009 the Esteve pharmaceutical joined the Obra Social La Caixa and the Generalitat, through the departments of Health and Economy and Coneixement, and the Clinic Foundation. Hivacat coordinator is the researcher Christian Brander, Harvard hired by the Generalitat Icrea program. Since its founding twenty years ago, IrsiCaixa has received 3.1 million euros from the Obra Social La Caixa.

Hivacat has launched eight lines of research addressing major obstacles in the development of HIV vaccines, both preventive and therapeutic. “One of the projects is the therapeutic vaccine candidate HTI. In 2014 came to a point that needed a high volume of investment and decided to form a spin-off that acquires the rights and seeks private investment, “says Naval, companies with experience in the health sector and current director of the Foundation Bosch i Gimpera).

Ysios participated in the development of the business model and has led the investment round (the bottom Ysios Biofund II provides 3.75 million) with Caixa Capital Risc, a regular partner in the main operations of the sector, and Johnson & Johnson Innovation. The operation has been advised by the law firm RCD. Aelix joined his advice to Karen Wagner, Ysios; Jose Antonio Mesa, Caixa Capital Risc; Jordi Naval, co-founder and a representative of JJDC. The company currently has a team of four people in the Parc Cientific Barcelona.

Courtesy Car Service Barcelona

Chauffeur Barcelona airport

Car Service Madrid

Forbes list 2016

A barcelonian 27 years old, enters the list of young talents ‘Forbes’

Pablo Pantaleoni Medtep

The Barcelonian entrepreneur Pablo Pantaleoni already appears in the final list that Forbes magazine has just published with 600 young talents under 30 who “are called to change the rules in the world”. Pantaleoni, 27, founded by the Catalan Jacob Suñol also a health platform, Medtep, which allows doctors to monitor their patients via mobile phones and computers, allowing higher quality of health. “I’m very happy,” says the young entrepreneur with hot news. “I want to share the credit with Jacob (Suñol). None of this would be possible without it. Medtep is today what is the vision of the two.

This is the fifth edition in which Forbes selects men and women under 30 who are “changing the rules” and that have impacted the world for its boldness, creativity and brilliance. “Until recently, being young was an obstacle to career success. The years allowed access to more resources, knowledge and money, “says the magazine. “The technology era has changed everything and now have less than 30 years it is an advantage.”

The process for drawing up the list is intense. Forbes evaluates more than 15,000 candidates in 20 different categories and ultimately selected 600 young and bright. They are all Americans or US residents, as in the case of Pantaleoni, who lives in San Francisco. Some names that share the Catalan businessman panel this year are: Stephen Curry, NBA player; John Boyega, the latest Star Wars movie, or the model Ashley Graham.

The young man studied at the Swiss School, she studied Economics at UPF and worked for the GVC financial group in Switzerland, where he met Suñol, with whom he founded in 2011 Medtep. “There is nothing more rewarding than entrepreneurial initiative” says, “because you work for yourself but also for society, to get people to live more healthily,” the youngest finalist, who notes that appear on this list will give visibility to rare and chronic diseases because many patients have improved their health with a more precise treatment based on information obtained by the platform. Medtep, which has 120,000 members, provides information to physicians about the lifestyle of their patients and the level of follow-up treatment. It also offers a personalized patient care by promoting the necessary changes to improve their health and quality of life. The company serves also to insurance companies and pharmaceutical companies.

Medtep is under the umbrella of the most important global health accelerator, StartUp Health and has closed a round of funding of two million. Precisely the founder of this accelerator, Unity Stoakes was who introduced Forbes Pantaleoni’s candidacy in the belief that it has a promising future.

Courtesy Car Service Barcelona

Chauffeur Barcelona airport

Car Service Madrid

Almirall purchase ThermiGen

The deal values the company based in Dallas in about 80 million dollars

Almirall Factory Barcelona

Almirall has executed its purchase option to acquire 100% of the share capital of ThermiGen, private aesthetic medical technology company based in Dallas, specializes in the development and production of energy systems regulated by thermistors for plastic surgery and aesthetic dermatological applications.

Last September Almirall acquired a 7.7% ThermiGen 5 million dollars (4.6 million euros) and paid 2.5 million dollars (2.3 million euros) for the right of option to acquire up to 100% of the company business worth close to 80 million dollars (73.5 million euros).

The Spanish company has stressed that, following the acquisition, the sum of ThermiGen portfolio of technology and will provide a commercial platform in the segment of energy-based devices; a model of “constant” business and management “experience and a strong track record” team.

Under the agreement, the transaction will be completed during the month, conditional and subject to compliance with certain conditions being operation; specifically, Almirall expects to close this transaction on 31 January.

The Spanish pharmaceutical, through its president, Jorge Gallardo, stressed that this operation is a first step to establish itself in the market of aesthetic and continue consolidating its strategy in the area of dermatology.

The ThermiGen product portfolio is based on the ‘hot science’: through technology ‘SmartTip’ doctors are allowed to use temperature as a parameter to treat a variety of aesthetic conditions of soft tissues and nervous.

This technology is used for various non-invasive and minimally invasive procedures and offers significant potential for use in multiple indications, as highlighted Almirall in a communication sent Monday to the National Securities Market Commission (CNMV).

The product of the American company ThermiRF first aesthetic medical device by the FDA (Food and Drug Administration USA) approved uses controlled radiofrequency for use in dermatological procedures and general surgery for temperature and electrocoagulation hemostasis, and to create lesions in the nervous tissue.

ThermiGen, founded in June 2012, also has the worldwide rights to market ThermiSmooth 250, which works using a specially designed handpiece, controlled by a thermistor which provides the necessary heat to the surface of the skin.

Last year, the company posted 11.4 million dollars (10.4 million euros) in revenues and expects to close 2015 with around 30 million dollars (27.5 million euros) in sales and positive operating results.

Courtesy

Barcelona Car Service Airport

Car Service Barcelona to Cruise Port

Car Service Barcelona

Chauffeur Barcelona airport

Car Service Madrid